HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis

Inclusion Criteria:

• Diagnosis of seborrheic dermatitis of the scalp

• PGA of 2 (mild) or greater at baseline

• TDSS score at baseline of 2 or greater, for both scaling and inflammation

• Must agree to use of non-medicated shampoos during study period; must refrain from useof other medicated scalp products during the trial

Exclusion Criteria:

• Use of any topical or oral products that would affect assessment of the scalp SDcondition, in the opinion of the primary investigator, within the following periodsprior to baseline:

• Medicated shampoos within 2 weeks of baseline

• Topical scalp medications within 2 weeks of baseline

• Oral medications affecting the scalp within 4 weeks of baseline

• Other medications determined by the investigator to potentially affect theassessment of SD = washout to be determined by the investigator, as appropriateto the known medication properties

• Any current or past medical condition, including active dermatitis or any otherdermatological condition, which might interfere with assessment of dandruff

• Patients using any medications that may increase photosensitivity, and thus pose arisk when undergoing LaserComb therapy

• Patients with known adverse reactions, allergy or hypersensitivity to laser lightcomponents/light sensitivity conditions

• Patients who have received any investigational drug within 30 days prior to studyentry.